TLDR
- CANF surges 23% after Phase IIa safety win in pancreatic cancer
- Namodenoson clears safety goal in advanced PDAC trial
- Can-Fite stock rallies on positive pancreatic study data
- Phase IIa results lift CANF shares on strong safety profile
- CANF gains as pancreatic cancer trial meets key endpoint
CANF stock surged after the company reported positive Phase IIa pancreatic cancer data. Shares traded near $6.00 and gained about 23.45% during the latest session. The move followed strong market activity and new clinical results from its namodenoson program.
Phase IIa Study Confirms Safety in Advanced PDAC
Can-Fite BioPharma Ltd. announced that its Phase IIa open-label study met the primary safety endpoint. The trial evaluated namodenoson in patients with advanced pancreatic ductal adenocarcinoma. These patients had progressed after receiving prior systemic therapies.
The study enrolled 20 patients with advanced metastatic disease and varied performance status. All participants had received at least one prior treatment regimen. The company reported that namodenoson was very well tolerated in this heavily pretreated group.
Moreover, researchers identified no new safety signals during the study period. The safety profile remained consistent with prior oncology trials. Therefore, the findings support continued clinical development in pancreatic cancer.
Secondary Endpoints and Ongoing Survival Follow-Up
In addition to safety, the study assessed overall survival and progression-free survival. Survival monitoring remains ongoing as data continue to mature. At the data cut-off, one-third of enrolled patients remained alive.
The company expects to present updated survival outcomes at future scientific meetings. These results will provide further clarity on the drug’s clinical benefit. Can-Fite BioPharma Ltd. continues follow-up assessments.
Namodenoson acts as a selective A3 adenosine receptor agonist. Preclinical models demonstrated anti-tumor activity in pancreatic cancer settings. Furthermore, researchers continue to evaluate the drug in advanced liver cancer trials.
Regulatory Status and Corporate Background
Namodenoson has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of pancreatic cancer. This designation supports development for rare diseases with high unmet need. It also provides potential regulatory incentives and market exclusivity benefits.
Can-Fite BioPharma Ltd. focuses on small molecule drugs targeting cancer and inflammatory diseases. The company operates from Israel and maintains a pipeline of proprietary compounds. Its programs include therapies for liver cancer and other inflammatory conditions.
Pancreatic ductal adenocarcinoma remains one of the most aggressive cancers worldwide. Treatment options remain limited, especially after prior therapy failure. Can-Fite BioPharma Ltd. aims to advance namodenoson as a potential therapeutic option.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
